非鳞非小细胞肺癌中PD-L1表达的临床病理与基因组关联
该回顾性研究纳入909例非鳞非小细胞肺癌,比较PD-L1阴性、低表达和高表达三组的临床病理特征及基因组改变。高表达与吸烟暴露、晚期分期、高TMB相关;阴性表达与STK11、EGFR等突变及CD274、PDCD1LG2、JAK2拷贝数丢失相关。CD274丢失者免疫治疗应答率更低、PFS更短。
要点
- 高PD-L1表达与吸烟暴露、晚期分期、高TMB相关
- PD-L1阴性表达与STK11、EGFR突变及CD274/PDCD1LG2/JAK2丢失相关
- CD274丢失者免疫治疗应答率更低、PFS更短
核心结论
- 非鳞NSCLC中PD-L1表达与特定基因组改变及临床病理特征相关。
研究设计与样本
- 回顾性研究纳入909例成功完成PD-L1评估及靶向NGS的非鳞NSCLC。
- 按PD-L1 TPS分为阴性(<1%)、低(1%-49%)、高(≥50%)三组比较。
- 多重比较校正后Q值<0.25视为显著。
主要发现
- 高PD-L1表达组相比低和阴性组,中位吸烟包年数分别为25、20、20(P=0.01)。
- 高PD-L1表达组相比低和阴性组,晚期诊断比例分别为76%、67%、61%(P<0.001)。
- 高PD-L1表达组相比低和阴性组,中位TMB分别为12.2、10.6、10.6突变/兆碱基(P<0.001)。
- 阴性PD-L1表达相比高表达,STK11突变19% vs 5%(Q<0.001),EGFR突变22% vs 11%(Q<0.001)。
- CD274丢失者相比无丢失者,免疫治疗应答率23% vs 9%(P=0.006),PFS 3.3 vs 2.0个月(P=0.002)。
关键数值与推荐
- PD-L1阴性表达相比高表达,CTNNB1突变4.3% vs 0.4%(Q=0.04),APC突变5% vs 1%(Q=0.17),SMARCA4突变9% vs 4%(Q=0.20)。
- 阴性PD-L1表达相比高表达,CD274拷贝数丢失28% vs 6%(Q<0.001),PDCD1LG2丢失28% vs 6%(Q<0.001),JAK2丢失27% vs 7%(Q<0.001)。
- 阴性PD-L1表达相比高表达,9p染色体臂丢失23% vs 10%(Q=0.04),1q获得46% vs 21%(Q<0.001)。
- 高PD-L1表达相比阴性表达,CD274拷贝数获得11% vs 3%(Q=0.01),PDCD1LG2获得11% vs 3%(Q=0.01)。
临床怎么用
- 非鳞NSCLC评估PD-L1表达时需结合吸烟史、分期及TMB等临床病理特征。
- PD-L1阴性表达者应关注STK11、EGFR突变及CD274/PDCD1LG2/JAK2拷贝数丢失。
- CD274丢失可能提示免疫治疗应答率低和PFS短,需谨慎选择免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small-cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. MATERIALS AND METHODS: Consecutive nonsquamous NSCLCs with successful PD-L1 assessment and targeted next-generation sequencing were included in this retrospective study. Clinicopathological characteristics, gene mutations, and copy number changes in gene and chromosomal arms were compared among three PD-L1 expression groups: negative (TPS < 1%), low (TPS 1%-49%), and high (TPS ≥ 50%). A Q-value <0.25 was considered significant after multiple comparisons correction. RESULTS: A total of 909 nonsquamous NSCLCs were included. High PD-L1 expression compared with low and negative PD-L1 expression was associated with increased tobacco exposure (median pack-years: 25 versus 20 versus 20, respectively; P = 0.01), advanced stage at diagnosis (76% versus 67% versus 61% with advanced stage of disease, respectively; P < 0.001), and higher tumor mutational burden (TMB) (median 12.2 versus 10.6 versus 10.6 mutations/megabase, respectively; P < 0.001). Negative PD-L1 expression when compared with high PD-L1 expression was associated with: mutations in STK11 (19% versus 5%; Q < 0.001), EGFR (22% versus 11%; Q < 0.001), CTNNB1 (4.3% versus 0.4%; Q = 0.04), APC (5% versus 1%; Q = 0.17), and SMARCA4 (9% versus 4%; Q = 0.20); copy number loss of CD274 (PD-L1, 28% versus 6%; Q < 0.001), PDCD1LG2 (PD-L2, 28% versus 6%; Q < 0.001), and JAK2 genes (27% versus 7%; Q < 0.001), loss of chromosomal arm 9p (23% versus 10%; Q = 0.04), and gain of 1q (46% versus 21%; Q < 0.001). High PD-L1 expression compared with negative PD-L1 expression was associated with copy number gain of CD274 (11% versus 3%; Q = 0.01) and PDCD1LG2 (11% versus 3%; Q = 0.01). NSCLCs with CD274 loss, compared with those without loss, had a lower response rate (23% versus 9%; P = 0.006) and shorter progression-free survival (3.3 versus 2.0 months; P = 0.002) on immunotherapy. CONCLUSIONS: PD-L1 expression is associated with specific genomic alterations and clinicopathologic characteristics in nonsquamous NSCLC.
引用
- Lamberti G, Spurr LF, Li Y, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020. PMID: 32171752. doi:10.1016/j.annonc.2020.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。